Singapore-based Brano Therapeutics secured $6.8 million in seed funding to advance new heart failure treatments focused on HFpEF, a condition still marked by limited therapy options. The financing is intended to support development of innovative treatment approaches targeting mechanisms underlying HFpEF. The company’s funding round signals continued investor attention on cardiovascular unmet need segments where traditional pathways have under-delivered. By positioning the program around HFpEF biology, Brano aims to translate novel targets into therapeutic candidates that can differentiate in a crowded clinical landscape. This comes as heart failure drug development increasingly emphasizes outcome-driven trials and stratified patient populations—areas where early translational data can strongly influence the speed of clinical entry and partnership potential.